Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Regulation

Peptides

FDA Advisers Narrowly Recommend Allowing Six Unapproved Peptides for Compounding

The panel’s close votes set up an FDA review that could lead to public rulemaking to widen access to popular but unproven peptides.

FDA Sets July Review of Compounded Peptides as HHS Backs Wider Access